Akari TX

• Patients received subcutaneous nomacopan (30 mg once daily) with lesional mometasone from Day 1 to 21 of treatment and nomacopan only …

[Read more...] about Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology 

• Preclinical data show investigational intravitreal long-acting PASylated-nomacopan (PAS-nomacopan) effective in inhibiting choroidal neovascularization (CNV), …

[Read more...] about Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atropy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC)

NEW YORK and LONDON, March 21, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative …

[Read more...] about Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

Broad-acting antihistamine has potential in number of disease areas with unmet clinical need NEW YORK and LONDON, March 09, 2022 (GLOBE NEWSWIRE) -- Akari …

[Read more...] about Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch

NEW YORK and LONDON, March 8, 2022 – Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative …

[Read more...] about Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering